MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 317897 | Name: Fluspirilene
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Fluspirilene is a long-acting diphenylbutylpiperidine antipsychotic that acts primarily as a high-affinity antagonist at dopamine D2 receptors, with additional activity at serotonin 5-HT2 receptors. By inhibiting dopaminergic neurotransmission in mesolimbic pathways, it reduces positive symptoms of schizophrenia while exerting minimal sedative effects. Fluspirilene’s extended half-life allows for once-weekly intramuscular administration, offering sustained plasma levels for improved compliance in maintenance therapy.

Chemical Structure

Fluspirilene
Fluspirilene
CAS#1841-19-6

Theoretical Analysis

MedKoo Cat#: 317897

Name: Fluspirilene

CAS#: 1841-19-6

Chemical Formula: C29H31F2N3O

Exact Mass: 475.2435

Molecular Weight: 475.57

Elemental Analysis: C, 73.24; H, 6.57; F, 7.99; N, 8.84; O, 3.36

Price and Availability

Size Price Availability Quantity
10mg USD 450.00 2 Weeks
25mg USD 700.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Fluspirilene; Redeptin; Imap; Fluspirileno; Imap Fluspirileno; Fluspiriline; Fluspirilen; McN-JR 6218; R 6218; R6218; R-6218;
IUPAC/Chemical Name
8-[4,4-bis(4-fluorophenyl)butyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
InChi Key
QOYHHIBFXOOADH-UHFFFAOYSA-N
InChi Code
InChI=1S/C29H31F2N3O/c30-24-12-8-22(9-13-24)27(23-10-14-25(31)15-11-23)7-4-18-33-19-16-29(17-20-33)28(35)32-21-34(29)26-5-2-1-3-6-26/h1-3,5-6,8-15,27H,4,7,16-21H2,(H,32,35)
SMILES Code
O=C1NCN(C2=CC=CC=C2)C13CCN(CCCC(C4=CC=C(F)C=C4)C5=CC=C(F)C=C5)CC3
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 475.57 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Kyro GW, Martin MT, Watt ED, Batista VS. CardioGenAI: a machine learning- based framework for re-engineering drugs for reduced hERG liability. J Cheminform. 2025 Mar 5;17(1):30. doi: 10.1186/s13321-025-00976-8. PMID: 40045386; PMCID: PMC11881490. 2: Bhattacharya K, Bhattacharjee A, Chakraborty M, Das D, Paudel KR. From Antipsychotic to Neuroprotective: Computational Repurposing of Fluspirilene as a Potential PDE5 Inhibitor for Alzheimer's Disease. J Comput Chem. 2025 Jan 15;46(2):e70029. doi: 10.1002/jcc.70029. PMID: 39797567. 3: Dhaka P, Singh A, Nehul S, Choudhary S, Panda PK, Sharma GK, Kumar P, Tomar S. Disruption of Molecular Interactions between the G3BP1 Stress Granule Host Protein and the Nucleocapsid (NTD-N) Protein Impedes SARS-CoV-2 Virus Replication. Biochemistry. 2025 Feb 18;64(4):823-840. doi: 10.1021/acs.biochem.4c00536. Epub 2024 Dec 21. PMID: 39708056. 4: Kong Y, Zhu W, Zhang Z, Sun W, Cui G, Chen H, Wang H. Fluspirilene exerts an anti-glioblastoma effect through suppression of the FOXM1-KIF20A axis. Neoplasma. 2024 Aug;71(4):333-346. doi: 10.4149/neo_2024_230909N479. PMID: 39267533. 5: Kim WJ, Ryu JY, Chang CS, Cho YJ, Choi JJ, Hwang JR, Choi JY, Lee JW. Anticancer effect of the antipsychotic agent penfluridol on epithelial ovarian cancer. J Gynecol Oncol. 2025 Mar;36(2):e28. doi: 10.3802/jgo.2025.36.e28. Epub 2024 Aug 27. PMID: 39223944; PMCID: PMC11964974. 6: Shamsi A, Khan MS, Altwaijry N, Hassan N, Shahwan M, Yadav DK. Targeting PDE4A for therapeutic potential: exploiting drug repurposing approach through virtual screening and molecular dynamics. J Biomol Struct Dyn. 2024 Jan 29:1-13. doi: 10.1080/07391102.2024.2308764. Epub ahead of print. PMID: 38287492. 7: Bhattacharya K, Bhattacharjee A, Chakraborty M. Assessing the potential of Psidium guajava derived phytoconstituents as anticholinesterase inhibitor to combat Alzheimer's disease: an in-silico and in-vitro approach. J Biomol Struct Dyn. 2025 May;43(8):4240-4257. doi: 10.1080/07391102.2024.2301930. Epub 2024 Jan 11. Erratum in: J Biomol Struct Dyn. 2024 Aug 5:1. doi: 10.1080/07391102.2024.2385611. PMID: 38205777. 8: Dutt M, Kumar A, Rout M, Dehury B, Martinez G, Ndishimye P, Kelvin AA, Kelvin DJ. Drug repurposing for Mpox: Discovery of small molecules as potential inhibitors against DNA-dependent RNA polymerase using molecular modeling approach. J Cell Biochem. 2023 May;124(5):701-715. doi: 10.1002/jcb.30397. Epub 2023 Mar 22. PMID: 36946432; PMCID: PMC10473176. 9: Tabatabaei Dakhili SA, Greenwell AA, Yang K, Abou Farraj R, Saed CT, Gopal K, Chan JSF, Chahade JJ, Eaton F, Lee C, Velázquez-Martínez CA, Crawford PA, Glover JNM, Al Batran R, Ussher JR. The Antipsychotic Dopamine 2 Receptor Antagonist Diphenylbutylpiperidines Improve Glycemia in Experimental Obesity by Inhibiting Succinyl-CoA:3-Ketoacid CoA Transferase. Diabetes. 2023 Jan 1;72(1):126-134. doi: 10.2337/db22-0221. PMID: 36256885. 10: Ma X, Mei J, Gao W, Xu W, Ahmad S, Ai H. Recognition of Aβ oligomer by LilrB2 acceptor: a tetracoordinated zipper mechanism. J Mol Model. 2022 Sep 20;28(10):322. doi: 10.1007/s00894-022-05315-4. PMID: 36125588. 11: Heemskerk MT, Korbee CJ, Esselink JJ, Dos Santos CC, van Veen S, Gordijn IF, Vrieling F, Walburg KV, Engele CG, Dijkman K, Wilson L, Verreck FAW, Ottenhoff THM, Haks MC. Repurposing diphenylbutylpiperidine-class antipsychotic drugs for host-directed therapy of Mycobacterium tuberculosis and Salmonella enterica infections. Sci Rep. 2021 Oct 4;11(1):19634. doi: 10.1038/s41598-021-98980-z. PMID: 34608194; PMCID: PMC8490354. 12: Lao K, Zhang R, Dai Y, Luan J, Guo N, Xu X, Zhang Y, Gou X. Identification of novel Aβ-LilrB2 inhibitors as potential therapeutic agents for Alzheimer's disease. Mol Cell Neurosci. 2021 Jul;114:103630. doi: 10.1016/j.mcn.2021.103630. Epub 2021 May 21. PMID: 34029694. 13: Fiolek TJ, Keel KL, Tepe JJ. Fluspirilene Analogs Activate the 20S Proteasome and Overcome Proteasome Impairment by Intrinsically Disordered Protein Oligomers. ACS Chem Neurosci. 2021 Apr 21;12(8):1438-1448. doi: 10.1021/acschemneuro.1c00099. Epub 2021 Mar 31. PMID: 33788542. 14: Chung I, Zhou K, Barrows C, Banyard J, Wilson A, Rummel N, Mizokami A, Basu S, Sengupta P, Shaikh B, Sengupta S, Bielenberg DR, Zetter BR. Unbiased Phenotype-Based Screen Identifies Therapeutic Agents Selective for Metastatic Prostate Cancer. Front Oncol. 2021 Mar 2;10:594141. doi: 10.3389/fonc.2020.594141. PMID: 33738243; PMCID: PMC7962607. 15: Chandra A, Gurjar V, Ahmed MZ, Alqahtani AS, Qamar I, Singh N. Exploring potential inhibitor of SARS-CoV2 replicase from FDA approved drugs using insilico drug discovery methods. J Biomol Struct Dyn. 2022 Aug;40(12):5507-5514. doi: 10.1080/07391102.2020.1871416. Epub 2021 Jan 25. PMID: 33491573. 16: Varalda M, Antona A, Bettio V, Roy K, Vachamaram A, Yellenki V, Massarotti A, Baldanzi G, Capello D. Psychotropic Drugs Show Anticancer Activity by Disrupting Mitochondrial and Lysosomal Function. Front Oncol. 2020 Oct 19;10:562196. doi: 10.3389/fonc.2020.562196. PMID: 33194631; PMCID: PMC7604408. 17: Petcherski A, Chandrachud U, Butz ES, Klein MC, Zhao WN, Reis SA, Haggarty SJ, Ruonala MO, Cotman SL. An Autophagy Modifier Screen Identifies Small Molecules Capable of Reducing Autophagosome Accumulation in a Model of CLN3-Mediated Neurodegeneration. Cells. 2019 Nov 27;8(12):1531. doi: 10.3390/cells8121531. PMID: 31783699; PMCID: PMC6953052. 18: Shaw V, Srivastava S, Srivastava SK. Repurposing antipsychotics of the diphenylbutylpiperidine class for cancer therapy. Semin Cancer Biol. 2021 Jan;68:75-83. doi: 10.1016/j.semcancer.2019.10.007. Epub 2019 Oct 13. PMID: 31618686; PMCID: PMC7152558. 19: Hind CK, Dowson CG, Sutton JM, Jackson T, Clifford M, Garner RC, Czaplewski L. Evaluation of a Library of FDA-Approved Drugs for Their Ability To Potentiate Antibiotics against Multidrug-Resistant Gram-Negative Pathogens. Antimicrob Agents Chemother. 2019 Jul 25;63(8):e00769-19. doi: 10.1128/AAC.00769-19. PMID: 31160293; PMCID: PMC6658780. 20: Cheng YS, Sun W, Xu M, Shen M, Khraiwesh M, Sciotti RJ, Zheng W. Repurposing Screen Identifies Unconventional Drugs With Activity Against Multidrug Resistant Acinetobacter baumannii. Front Cell Infect Microbiol. 2019 Jan 4;8:438. doi: 10.3389/fcimb.2018.00438. PMID: 30662875; PMCID: PMC6328479.